Results 311 to 320 of about 15,549,143 (355)
Some of the next articles are maybe not open access.
Challenges of Inpatient Glycemic Control
Journal of Nursing Care Quality, 2017Hyperglycemia occurs in more than 30% of hospitalized patients. The condition has been associated with higher mortality and poor outcomes. Systems to effectively treat dysglycemia have been put into place, although many focus on critical care areas.
Sally O, Gerard, Josephine, Ritchie
openaire +2 more sources
Guidelines for glycemic control
Clinical Cornerstone, 2004Glycemic control in diabetes patients continues to evolve as new medications are introduced and clinical trial data become available. The American Diabetes Association (ADA) guidelines for 2004, for the first time, provide targets for both preprandial and postprandial glucose levels.
openaire +2 more sources
Advances in Surgery, 2008
Glycemic control clearly improves outcome in critically ill patients. Remaining questions are how tight the control must be to obtain the most benefit without increasing the risk for severe hypoglycemia, and whether an acuity level exists in which this benefit is not clearly visualized. In other words, is this benefit only seen in severely ill patients?
Grant V, Bochicchio, Thomas M, Scalea
openaire +2 more sources
Glycemic control clearly improves outcome in critically ill patients. Remaining questions are how tight the control must be to obtain the most benefit without increasing the risk for severe hypoglycemia, and whether an acuity level exists in which this benefit is not clearly visualized. In other words, is this benefit only seen in severely ill patients?
Grant V, Bochicchio, Thomas M, Scalea
openaire +2 more sources
The Diabetes Educator, 2008
The improved understanding of glucoregulatory hor- mones has driven the development of new pharmacologic agents to treat type 2 diabetes. One new class of antihy- perglycemic medication is incretin mimetics (IMs). Incretin hormones potentiate insulin secretion following meal ingestion, a process that is impaired in patients with type 2 diabetes. GLP-1,
openaire +1 more source
The improved understanding of glucoregulatory hor- mones has driven the development of new pharmacologic agents to treat type 2 diabetes. One new class of antihy- perglycemic medication is incretin mimetics (IMs). Incretin hormones potentiate insulin secretion following meal ingestion, a process that is impaired in patients with type 2 diabetes. GLP-1,
openaire +1 more source
GLYCEMIC CONTROL AND HEART DISEASE
Nursing Clinics of North America, 2001The leading cause of death among patients with diabetes is cardiovascular disease with approximately 80% of all deaths being attributed to coronary heart disease. Acute myocardial infarctions (AMIs) in patients with diabetes are associated with an increased rate of reinfarction than those without diabetes. Following AMI, patients with diabetes are more
L, Colwell, L, Quinn
openaire +2 more sources
Glycemic Control and Diabetic Complications
Diabetes Care, 1992The relationship between glycemic control and diabetic complications remains unclear. Epidemiological studies reveal that ∼25% of diabetic individuals do not develop complications, irrespective of degree of glycemic control. Studies of genetic factors, including HLA type, capillary basement membrane thickness, genetic predisposition to hypertension ...
S, Strowig, P, Raskin
openaire +2 more sources
Antidepressant use and glycemic control
Psychopharmacology, 2013Past research on the association of antidepressant medication use with glycemic control abnormalities has produced mixed results.To examine the association of antidepressant use with glycemic control abnormalities and screen-positive diabetes in a representative population sample of US adults without a diagnosis of diabetes.Using data from adult ...
openaire +2 more sources
Constipation and glycemic control
Journal of Diabetes and its Complications, 2021Rebecca B N, Conway +2 more
openaire +2 more sources
Cervical cancer prevention and control in women living with human immunodeficiency virus
Ca-A Cancer Journal for Clinicians, 2021Philip E Castle, Vikrant V Sahasrabuddhe
exaly

